Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
NCT01349088 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · PHASE1/PHASE2 · withdrawn · last registry update 2025-05-02 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-04Results posted on the registry: AstraZeneca, Dato-DXd + Capecitabine (NCT05104866)
- 2025-09-15Phase 3 first posted: BioNTech SE, Pumitamig + Nab-paclitaxel/Paclitaxel (NCT07173751)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision